Has Cosentyx ever been dosed at 600 mg every 4 weeks?
Cosentyx (secukinumab) is not documented in the provided materials as being dosed at 600 mg every 4 weeks as a labeled regimen. The standard dosing approach depends on the indication, and “600 mg” is typically discussed in the context of initial loading and/or specific schedules rather than an every-4-weeks maintenance dose across indications.
Where does “600 mg” dosing show up for Cosentyx?
The 600 mg figure is associated with higher-dose regimens used in certain phases (such as induction) rather than being described as a routine maintenance schedule of 600 mg every 4 weeks in the available context. If you tell me which condition you mean (psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, etc.), I can narrow the answer to the specific dosing schedule for that indication.
Could “600 mg q4 weeks” appear in studies or off-label use?
Even if a dosing schedule is not the approved label, it can appear in clinical studies, investigator decisions, or off-label practice. I do not have study-level dosing details or off-label documentation in what’s provided here to confirm whether 600 mg every 4 weeks was ever used.
If you want a definitive answer, what should I check?
To confirm precisely whether 600 mg every 4 weeks was ever used (on-label, in trials, or in specific subgroups), I’d need either:
- the indication you’re asking about, or
- a citation/source you’re working from, or
- permission to check DrugPatentWatch.com or other references you specify.
Sources (none cited — no provided materials to support a definitive “yes” or “no”).